Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The COVID-19 pandemic continued to rage in 2021, but this was increasingly an unequal pandemic, with rich countries receiving millions of doses of vaccine and ending lockdowns and travel bans. It was also a year when policymakers started to prepare for the next inevitable pandemic.
The FREEDOM studies evaluated exenatide delivered via an implanted minipump in patients with type 2 diabetes; the final study evaluated cardiovascular outcomes but offers up more questions than answers.
AI-based models may amplify pre-existing human bias within datasets; addressing this problem will require a fundamental realignment of the culture of software development.
mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study takes the first step toward this goal.
Two early-phase clinical trials show impressive response rates and symptom improvement with the selective KIT inhibitor avapritinib, which will provide a much-needed new treatment option for patients.
An effective and scalable cure strategy is a top priority for the HIV research field; this Review discusses recent advances, knowledge gaps, and priority research areas for the next 5 years.
New research can help policymakers make evidence-based decisions about the risks and benefits of in-person schooling; strategic use of the available data will be key to getting this right.
The STORMS tool provides guidance for concise and complete reporting of microbiome studies to facilitate manuscript preparation, peer review, reader comprehension of publications, and comparative analysis of published results.